MODULATION OF MUTANT CALRETICULIN-DRIVEN ONCOGENESIS IN MYELOPROLIFERATIVE NEOPLASMS BY CLASSICAL HLA GENES
EHA Library, Velizar Shivarov, 385451
MODERN DIAGNOSTIC CAPABILITIES OF THE OPHTHALMOLOGICAL STATUS OF PATIENTS WITH ONCO-HEMATOLOGICAL DISEASES.
EHA Library, Mayya V Vorobyeva, 387773
DIGITAL-HEALTH AND REMOTE MONITORING FOR PATIENTS RECEIVING AZACITIDINE AT HOME. A FURTHER STEP TOWARDS HUMANIZATION AND PATIENT-CENTERED MEDICINE
EHA Library, Isabel Gonzalez-Gascon-y-Marin, 387777
OPIOID USE REDUCTION BY OXYCODONE MORPHINE FORMULARY SWITCH
EHA Library, Catharina Hazenberg, 387778
ANEMIA IN HEMATOLOGIC MALIGNANCIES: NOT ONLY A SYMPTOM.
EHA Library, Oumayma Hari, 387783
EFFECT OF NARRATIVE NURSING ON ANXIETY, DEPRESSION AND STIGMA IN PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Library, Jie Tang, 387784
LONG TERM PEJORATIVE IMPACT OF LENALIDOMIDE MAINTENANCE ON HEALTH-RELATED QUALITY OF LIFE IN CHRONIC LYMPHOCYTIC LEUKEMIA. ANCILLARY STUDY OF THE PHASE III CLL6-RESIDUUM TRIAL
EHA Library, Stephane WASSE, 387787
MORE EFFICIENT DELIVERY OF HIGH-COST STANDARD-OF-CARE THERAPIES IN RELAPSED MULTIPLE MYELOMA USING REAL-TIME FEEDBACK OF PATIENT-REPORTED OUTCOME MEASURES: THE MY-PROMPT-2 TRIAL
EHA Library, Elizabeth Moore, 387788
CONSENSUS FROM AN EXPERT PANEL ON THE CURRENT MANAGEMENT OF SECONDARY IMMUNODEFICIENCY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN SPAIN
EHA Library, Elena Cabezudo Perez, 387789
SAFETY OF 30 MINUTES INFUSION OF RITUXIMAB BIOSIMILAR. A COHORT STUDY.
EHA Library, Ernesto Pérez, 387791
POLYPHARMACY IN HEMATOLOGY PRACTISE: A SINGLE CENTER EXPERIENCE
EHA Library, Abdulkadir Karismaz, 387792
ISA-KD IN NOT TRANSPLANT CANDIDATES RRMM. EXPERIENCE IN REAL LIFE.
EHA Library, Dunia De Miguel Llorente, 387793
PREDICTING HEMATOLOGICAL MALIGNANCIES USING COMPLETE BLOOD CELL COUNTS FROM PRIMARY CARE
EHA Library, Mathilde Christensen, 387794
PROFESSIONAL BURNOUT AMONG HEMATOLOGISTS AFTER THE OUTBREAK OF THE COVID-19 PANDEMIC AND ASSOCIATED FACTORS
EHA Library, Olga Aleshina Gavrilina, 387795
ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0
EHA Library, Barbara Kiesewetter, 387797
BURDEN OF SEVERE INFECTIONS IN PRIMARY IMMUNODEFICIENCY DISEASES
EHA Library, Saurabh Aggarwal, 387799
NATURAL AND AGE-RELATED VARIATION IN CIRCULATING HUMAN HEMATOPOIETIC STEM CELLS
EHA Library, Nili Furer, 387803
CLONAL DIFFERENTIATION TRAJECTORIES OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA AT SINGLE CELL LEVEL
EHA Library, Adrien Jolly, 387805
METABOLIC PLASTICITY REVEALS A TARGETABLE VULNERABILITY IN LEUKEMIA
EHA Library, Guillaume Andrieu, 387806
P53 ORCHESTRATES SPATIO-TEMPORAL EPIGENOME REWIRING TO TRANSCRIPTIONALLY PREVENT MALIGNANT TRANSFORMATION
EHA Library, Biola M Javierre, 387809
PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL
EHA Library, Elias Jabbour, 387810
IMPACT OF IKZF1 DELETION IN RELAPSED AND/OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH CD19-CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
EHA Library, Zihong Cai, 387813
OUTCOME OF OLDER PATIENTS (>55 YRS) WITH NEWLY DIAGNOSED PH/BCR:ABL POSITIVE ALL PROSPECTIVELY TREATED ACCORDING TO PEDIATRIC-BASED, AGE-ADAPTED GMALL PROTOCOLS
EHA Library, Fabian Lang, 387814
CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910
EHA Library, Ryan Mattison, 387815
CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703
EHA Library, Matthew Wieduwilt, 387817
A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY
EHA Library, Nicholas Short, 387818
MNX1-ACTIVATING ENHANCER HIJACKING EVENTS IN ACUTE MYELOID LEUKEMIA WITH DELETIONS ON CHROMOSOME 7Q
EHA Library, Anna Riedel, 387820
­­­MULTIPARAMETER PREDICTION OF MYELOID NEOPLASIA RISK
EHA Library, Muxin Gu, 387821
IL-9 SECRETED BY LEUKEMIA STEM CELLS INDUCES THE EPIGENETIC ACTIVATION OF BM-INFILTRATING CD4+ T CELLS IN ACUTE MYELOID LEUKEMIA
EHA Library, Ramin Radpour, 387826
DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
EHA Library, Diego A Pereira-Martins, 387827
UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIRZATINIB
EHA Library, Juan Miguel Bergua Burgues, 387832
ANALYSIS OF FACTORS ASSOCIATED WITH LONG-TERM SURVIVAL IN A LARGE ACUTE PROMYELOCYTIC LEUKEMIA (APL) PATIENT COHORT: A HARMONY ALLIANCE STUDY
EHA Library, Maria Teresa Voso, 387836
VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Library, Marius Bill, 387838
INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
EHA Library, Naveen Pemmaraju, 387839
IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
EHA Library, Eric Eldering, 387840
INHIBITION OF MYC TRANSLATION THROUGH TARGETING OF THE NEWLY IDENTIFIED PHB-EIF4F COMPLEX AS THERAPEUTIC STRATEGY INCHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
EHA Library, Anne Largeot, 387841
FOXO1-RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY
EHA Library, Marek MRAZ, 387842
VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
EHA Library, Othman Al-Sawaf, 387845
GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
EHA Library, Jennifer R. Brown, 387846
EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME
EHA Library, Anna Maria Frustaci, 387847
TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL
EHA Library, Arnon P. Kater, 387848
TIMING AND CLONAL TRAJECTORY TO CHRONIC MYELOID LEUKAEMIA DRIVEN BY THE PHILADELPHIA CHROMOSOME
EHA Library, Aleksandra Kamizela, 387850
MECHANISMS OF TROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TREATMENT WITH PONATINIB AND OTHER TYROSINE KINASE INHIBITORS
EHA Library, Ernesto Jose Cuenca Zamora, 387853
IDENTIFICATION OF NOVEL FACTORS CONTROLLING NON GENETIC CELL PLASTICITY IN CHRONIC MYELOID LEUKEMIA
EHA Library, Guido Baselli, 387854
FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
EHA Library, Thomas Ernst, 387856
NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
EHA Library, Andreas Hochhaus, 387857
GATA2B HAPLOINSUFFICIENCY CAUSES ABERRANT TRANSCRIPTIONAL REGULATORY SIGNATURES IN HSPCS RESULTING IN MYELOID AND ERYTHROID DYSPLASIA IN ZEBRAFISH
EHA Library, wei zhang, 387860
LOSS OF HEMATOPOIETIC PROGENITORS HETEROGENEITY IS AN ADVERSE PROGNOSTIC FACTOR IN MYELODYSPLASTIC SYNDROMES
EHA Library, Nicolas Chapuis, 387862
CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
EHA Library, Uwe Platzbecker, 387865
KER-050 TREATMENT IMPROVED MARKERS OF ERYTHROPOIETIC ACTIVITY AND HEMATOPOIESIS OVER SIX MONTHS WHICH RESULTED IN HEMATOLOGICAL RESPONSES ACROSS A BROAD, LOWER-RISK MDS POPULATION
EHA Library, Aristoteles Giagounidis, 387866
MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY
EHA Library, Nicolas Chapuis, 387869
HIGHER MDMX EXPRESSION WAS ASSOCIATED WITH HYPOMETHYLATING AGENT RESISTANCE AND WORSE SURVIVAL IN MYELODYSPLASTIC SYNDROME PATIENTS, INFERRING IT A POTENTIAL THERAPEUTIC TARGET
EHA Library, Yu-Hung Wang, 387871
HEPATOCYTE TOLL-LIKE RECEPTORS MEDIATE THE HEPCIDIN INFLAMMATORY RESPONSE TO PATHOGENS AND PATHOGEN-DERIVED LIGANDS
EHA Library, Oriana Marques, 387984
DISSECTING THE ROLE OF THE IMMUNOPHILIN FKBP12 IN HEPCIDIN REGULATION
EHA Library, Laura SILVESTRI, 387985
ANTI-NEOPLASTIC TREATMENT, BASED ON PRO DATA REPORTED THROUGH A MHEALTH APP SOLUTION IN MULTIPLE MYELOMA PATIENTS
EHA Library, Jannie Kirkegaard, 387772
QUALITY OF LIFE IMPAIRMENT IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO SUFFERED FROM RUSSIAN MILITARY AGGRESSION IN UKRAINE: A SINGLE CENTER EXPERIENCE
EHA Library, Tetiana Lymanets, 387774
QUALITY OF LIFE IN INDIAN ADULTS WITH IMMUNE THROMBOCYTOPENIA
EHA Library, Dhwani Ravi, 387775
THE PSYCHOLOGICAL EXPERIENCE AND BURDEN OF BLOOD CANCER FOR ADULT PATIENTS: A SYSTEMATIC REVIEW AND META-SYNTHESIS
EHA Library, Priyanka Mehta, 387779
CURRENT STATUS AND FACTORS INFLUENCING FEAR OF COVID-19 IN HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS: A CROSS-SECTIONAL STUDY
EHA Library, Fucong Peng, 387780
ARSENIC RETENTION IN TISSUES AND QUALITY OF LIFE IN PEDIATRIC ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ARSENICALS: A CROSS SECTIONAL STUDY
EHA Library, chao wu, 387781
BRIEF EVALUATION OF THE IMPACT OF THE WAR ON QUALITY OF LIFE OF UKRAINIAN PNH PATIENTS.
EHA Library, Olena Kyselova, 387782
ANALYSIS OF THE CURRENT SITUATION AND FACTORS INFLUENCING PSYCHOLOGICAL DISTRESS OF HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS IN THE LAMINAR FLOW WARD
EHA Library, Jing Wen, 387785
QUALITATIVE INTERVIEWS TO DESCRIBE BURDEN IN PATIENTS (PT) WITH THIRD-LINE OR LATER CLL/SLL WITH PRIOR EXPOSURE TO BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
EHA Library, Mona L Martin, 387786
ANXIETY AND DEPRESSION IN HEMATOLOGICAL MALIGNANCIES PATIENTS: FOCUS ON TREATMENT ADHERENCE
EHA Library, Dmitry E Vybornykh, 387790
NO DIFFERENCE IN SURVIVAL OUTCOMES BETWEEN IMMIGRANTS AND DANISH-BORN CITIZENS WITH A HEMATOLOGICAL MALIGNANCY: A NATIONWIDE, POPULATION-BASED REGISTER STUDY
EHA Library, Joachim Baech, 387796
SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE IN PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN’S DISEASE (IMCD): AN EXPLORATORY ANALYSIS OF THE SURVEY’S INTERNAL CONSTRUCT VALIDITY
EHA Library, Sudipto Mukherjee, 387798
OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT01599559)
EHA Library, Maurizio Martelli, 387801
DIFFERENTIAL TARGET PROFILES AND EFFICACY OF ADCLEC.SYN1 AND CD33-CARS IN HUMANIZED AML MODELS
EHA Library, Sascha Haubner, 387804
IDENTIFICATION AND CHARACTERIZATION OF GERMLINE NBN VARIANTS RELATED TO B-ALL PREDISPOSITION
EHA Library, Carolin Escherich, 387807
ATP CITRATE LYASE IS AN ESSENTIAL PLAYER OF THE METABOLIC REWIRING INDUCED BY PTEN LOSS DURING T-ALL DEVELOPMENT
EHA Library, Melania Tesio, 387808
TREATMENT OF POST-TRANSPLANT RELAPSE IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH BCP ALL USING CD19-CAR-T: A EUROPEAN RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA
EHA Library, Peter Bader, 387811
THE EFFECT OF IMMUNOGLOBULIN PROPHYLAXIS ON INFECTIOUS MORBIDITY IN PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS OF A RANDOMIZED CONTROLLED TRIAL
EHA Library, Kirsten Thus, 387812
DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Library, Jing Pan, 387816
COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL
EHA Library, Nicholas Short, 387819
MUTANT IDH1 HIJACKS DIFFERENTIATION PROGRAMS IN MYELOID PROGENITOR CELLS TO IMPAIR GRANULOCYTIC DIFFERENTIATION.
EHA Library, Mariam Hakobyan, 387822
ACUTE MYELOID LEUKEMIA STEM CELL SUBTYPES DEFINED BY MUTATIONS AND DIFFERENTIATION STATE REGULATE APOPTOTIC DEPENDENCY AND CLINICAL RESPONSE TO VENETOCLAX.
EHA Library, Alexander Waclawiczek, 387823
PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
EHA Library, Arran Dokal, 387824
NON-GENETIC RESISTANCE TO MENIN INHIBITION IN AML IS REVERSIBLE BY PERTURBATION OF KAT6A
EHA Library, Florian Perner, 387825
AML CONDITIONING OF THE BONE MARROW MICROENVIRONMENT THROUGH CCR1 LIGAND UP-REGULATION PROMOTES AML STEM CELL PROPAGATION AND IS MIMICKED BY AGEING
EHA Library, Xiying Ren, 387828
ADOPTIVELY INFUSED MEMORY-LIKE (ML) NATURAL KILLER (NK) CELLS ELICIT ADAPTIVE IMMUNE RESPONSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
EHA Library, Sergio Rutella, 387829
PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML
EHA Library, Pau Montesinos, 387830
A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
EHA Library, Steven Knapper, 387831
AN ENTIRELY ORAL REGIMEN OF ORAL-ATO, ATRA AND ASCORBIC ACID IN RISK-ADAPTED TREATMENT OF NEWLY-DIAGNOSED APL RESULTED IN EXCELLENT CLINICAL/MOLECULAR RESPONSES WITH DURABLE REMISSION
EHA Library, Harinder Gill, 387833
FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
EHA Library, Nigel Russell, 387834
NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
EHA Library, Frank Rücker, 387835
IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FROM QUANTUM-FIRST
EHA Library, Richard Schlenk, 387837
NATURAL CLONAL EVOLUTION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH BIMODAL CD49D EXPRESSION REVEALS CD49D PLASTICITY
EHA Library, Erika Tissino, 387843
BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL
EHA Library, Sigrid Skånland, 387844
OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.
EHA Library, Thomas Chatzikonstantinou, 387849
COMBINATION OF LARGE SPLEEN AND LOW IN VIVO KINASE INHIBITION IS AN EARLY PREDICTOR OF INFERIOR MOLECULAR RESPONSE AND POOR OUTCOMES IN CHRONIC MYELOID LEUKAEMIA
EHA Library, Hughes Tim, 387851
COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL
EHA Library, Nikola Čuřík, 387852
PROGNOSTIC FACTORS FOR 3-YEAR MAJOR MOLECULAR RESPONSE MAINTENANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE EUROPEAN STOP KINASE INHIBITORS (EURO-SKI) TRIAL
EHA Library, Markus Pfirrmann, 387855
EFFICACY OF LOW-DOSE TYROSINE KINASE INHIBITOR THERAPY AFTER ACHIEVING MAJOR MOLECULAR RESPONSE IN PERSONS WITH CHRONIC MYELOID LEUKAEMIA
EHA Library, Jiang Qian, 387858
HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY
EHA Library, Fabio Efficace, 387859
UBA1 NON-M41 VARIANTS ARE MORE AGGRESSIVE THAN UBA1 M41 VARIANTS IN THEIR HEMATOLOGICAL MANIFESTATIONS.
EHA Library, Maki Sakuma, 387861
POLYSOME INTERACTOME IN RPS14-DEFICIENT CELLS REVEALS THE INVOLVEMENT OF THE MRNA DECAY MACHINERY IN TRANSLATION SELECTIVITY.
EHA Library, ismael boussaid, 387863
DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
EHA Library, Valeria Santini, 387864
MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
EHA Library, Rami S. Komrokji, 387870
PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
EHA Library, Alex Bataller, 387872
TARGETING CONDITIONING-ELICITED NON-TRANSFERRIN-BOUND IRON BY TMPRSS6 SILENCING IMPROVES BONE MARROW TRANSPLANT OUTCOME
EHA Library, Francesca Vinchi, 387986

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings